Following a two-day public hearing, the Canadian Nuclear Safety Commission announced its decision Oct. 27 to renew the Atomic Energy of Canada Limited's (AECL) Chalk River Laboratories operating license for a period of five years. The license will be valid from Nov. 1 until Oct. 31, 2016.

Royal Philips Electronics has launched MicroDose Mammography, a full-field digital mammography system.

Citing significant variations in pediatric radiopharmaceutical doses and package inserts lacking pediatric doses, the authors of an article appearing in the November issue of Radiology indicated recently approved consensus guidelines for pediatric administered radiopharmaceutical doses may help solve the problem. 

The FDA has granted approval for Medtronic's Assurant Cobalt iliac balloon-expandable stent system.

In a retrospective cohort study of women using contraceptives, the FDA reported that the norelgestromin/ethinyl estradiol transdermal patch (Ortho Evra), drospirenone/ethinyl estradiol pill (Yaz) and the etonogestrel/estradiol vaginal ring (NuvaRing) put women at a higher risk for venous thromboembolism (VTEs) when compared with standard low-dose contraceptives.

The FDA has released new standard operating policies and procedures for staff of the Center for Biologics Evaluation and Research (CBER). Effective Nov. 1, the document will guide staff in developing and posting quarterly lists of potential serious risks, as identified by the Adverse Event Reporting System (AERS).

This session dives into the future of molecular oncology, introducing attendees to an array of topics, including: molecular targets and personalized treatments, with a focus on non-small cell lung cancer; novel PET tracers; the role of CT and MRI and radiogenomics.

This session reviews molecular imaging in orthopedic research; new developments in imaging for musculoskeletal pain and advances in agents and tracers for musculoskeletal malignancies, including their role in assessing early response to therapy, treatment planning and prognosis.